There is no FDA-approved medication for borderline personality disorder. Not one. Despite decades of psychiatric research, no regulatory agency anywhere in the world has approved a single drug specifically designed to treat BPD. This is not for lack of trying — Eli Lilly sponsored two large-scale randomized controlled trials of olanzapine, each enrolling more than 300 participants, and both failed to win approval. After that, the pharmaceutical industry largely walked away from BPD drug development altogether.
The disorder’s complexity simply does not yield to the kind of single-mechanism pharmacological fix that works for conditions like major depression or schizophrenia. What makes this absence so striking is the sheer volume of prescribing that happens anyway. More than 80 percent of BPD patients in the United States are on some form of pharmacotherapy, and roughly half take three or more psychiatric medications simultaneously. That is a staggering rate of off-label polypharmacy for a condition where the evidence base is, as the American Psychiatric Association now puts it, “scant.” The 2024 APA Practice Guideline for BPD — a landmark document that represents a major shift in clinical thinking — explicitly warns against the routine use of medications for core BPD symptoms and elevates structured psychotherapy, particularly dialectical behavior therapy, as the primary treatment. This article examines why no drug has cleared the approval bar for BPD, what the research actually shows about commonly prescribed medications, how polypharmacy became so entrenched, what the new APA guideline recommends, and what patients and families should understand about the current state of treatment.
Table of Contents
- Why Don’t Psychiatrists Have a Single Approved Drug for Borderline Personality Disorder?
- The Polypharmacy Problem — How 80 Percent of BPD Patients Ended Up on Medications That Don’t Work
- The Research That Failed — What Clinical Trials Actually Showed
- What the 2024 APA Practice Guideline Actually Recommends for BPD Treatment
- The Risks of Treating BPD with Off-Label Medications Long-Term
- What BPD Tells Us About the Limits of Biological Psychiatry
- Where BPD Treatment Goes From Here
- Conclusion
- Frequently Asked Questions
Why Don’t Psychiatrists Have a Single Approved Drug for Borderline Personality Disorder?
The simplest answer is that BPD is not a chemical imbalance problem. Depression can be framed, however imperfectly, around serotonin and norepinephrine signaling. Bipolar disorder involves identifiable shifts in mood-regulating circuitry. BPD is a personality disorder — rooted in patterns of emotional regulation, self-image instability, interpersonal turbulence, and impulsivity that develop over years and become woven into a person’s entire way of relating to the world. There is no single neurotransmitter knob to turn, no receptor to block or stimulate, that addresses that kind of pervasive dysfunction. The neurobiological underpinnings of BPD remain genuinely unclear. Researchers have identified differences in amygdala reactivity, prefrontal cortex functioning, and oxytocin signaling in people with BPD, but none of these findings has translated into a clear drug target.
Compare this to Alzheimer’s disease, where the amyloid and tau hypotheses — however debated — at least gave pharmaceutical companies a molecular target to pursue. BPD offers no comparable foothold. The disorder sits at the intersection of temperament, trauma history, attachment patterns, and learned behavioral responses, and no pill addresses that intersection. The practical consequence is that every medication prescribed for BPD is off-label, borrowed from the pharmacopeias of depression, psychosis, epilepsy, or anxiety. SSRIs, second-generation antipsychotics, anticonvulsants, and mood stabilizers have all been tried. None has consistently reduced overall BPD severity across well-designed trials. Lamotrigine, which generated early enthusiasm, failed to demonstrate beneficial effects in real-world effectiveness studies. The drugs may blunt a specific symptom — some anxiety here, some impulsive aggression there — but they do not treat the disorder itself.
The Polypharmacy Problem — How 80 Percent of BPD Patients Ended Up on Medications That Don’t Work
The gap between evidence and practice in BPD treatment is one of the widest in all of psychiatry. Despite zero approved drugs and scant evidence for off-label options, the prescribing numbers are remarkable. A New Zealand national database study found that the proportion of BPD patients on three or more psychotropic medications rose from 50 percent in 2014 to 55.9 percent in 2019 — the trend is getting worse, not better. Among adolescents with BPD, 64.85 percent were prescribed medications, and of those, 79.40 percent received two or more unique medications, with a mean of 4.03 unique lifetime medications. These are young people accumulating complex drug regimens for a condition where the evidence does not support pharmacological treatment of core symptoms. How did this happen? Several forces converge. BPD patients present in acute distress — suicidal ideation, self-harm, emotional crises — and clinicians feel compelled to do something. Prescribing a medication is faster and more immediately actionable than arranging months of specialized psychotherapy.
Insurance systems often cover medications more readily than they cover the intensive therapy programs that actually work. And once a patient is on a medication, the inertia of continuation is powerful. Stopping a drug requires the clinical courage to say “this probably isn’t helping,” which risks destabilizing a patient who may attribute any stability they have to the pill. However, if a patient is genuinely stabilized and functioning well on a particular medication regimen, the calculus changes. The new APA guideline does not demand that all medications be immediately stripped away. It recommends medication review and reconciliation at least every six months, with a goal of identifying drugs that should be tapered or discontinued. The critical point is that medications should be time-limited and targeted at a specific, measurable symptom — not prescribed indefinitely as a vague hedge against emotional volatility. When a medication cannot demonstrate a clear benefit against a defined target, continuing it exposes the patient to side effects — weight gain, metabolic syndrome, sedation, tardive dyskinesia — with no offsetting therapeutic value.
The Research That Failed — What Clinical Trials Actually Showed
The story of BPD pharmacotherapy is partly a story of research methodology that was never adequate to the task. Most trials lasted only 6 to 12 weeks, which is absurdly short for a lifelong personality disorder. BPD symptoms fluctuate naturally over weeks and months; a brief trial cannot distinguish drug effects from the disorder’s own waxing and waning. Sample sizes were generally small, dropout rates were high — BPD patients are notoriously difficult to retain in studies — and follow-up was often inadequate. Perhaps most damning, many trials used depression and anxiety rating scales rather than BPD-specific outcome measures. This means that even when a drug showed a signal, it was often showing improvement in comorbid depression or anxiety, not in the core BPD features of identity disturbance, abandonment fear, dissociation, or unstable relationships. Of 87 medications used in clinical practice for BPD, studies existed on only 9 of them.
That leaves the vast majority of prescribing entirely unsupported by even a single trial. The Eli Lilly olanzapine program illustrates the scale of what failed. Two large, well-funded randomized controlled trials — the kind of studies that should be definitive — could not produce the evidence needed for FDA approval. after that, no major pharmaceutical company has mounted a comparable effort. The economics are straightforward: BPD drug development is expensive, the endpoint is unclear, and the probability of approval is low. Industry money flows toward conditions with clearer biological targets and more predictable regulatory pathways. This is unlikely to change unless a genuine breakthrough in understanding BPD neurobiology provides a new target worth pursuing.
What the 2024 APA Practice Guideline Actually Recommends for BPD Treatment
The APA published its second edition Practice Guideline for BPD in November 2024, led by George A. Keepers, M.D., with co-authors including Lois Choi-Kain, John M. Oldham, and Carla Sharp. This is only the second such guideline the APA has produced for BPD, and it represents a sharp departure from the more permissive approach to medication that characterized earlier clinical attitudes. The key conclusion is blunt: “While patients with BPD continue to be high utilizers of medications from almost all categories, scant evidence exists that these medications are of use in addressing core symptoms of the disorder and likely pose a variety of risks.” The guideline places structured psychotherapy — especially dialectical behavior therapy — as the primary treatment for BPD. DBT, developed by Marsha Linehan, directly targets the emotional dysregulation, distress intolerance, and interpersonal difficulties that define BPD. Other evidence-based psychotherapies, including mentalization-based treatment and transference-focused psychotherapy, are also supported.
The tradeoff is real: these therapies require trained clinicians, sustained patient engagement, and time. A typical DBT program runs for at least a year and involves weekly individual therapy, weekly skills group, and between-session coaching. That is a far heavier investment than writing a prescription, but it is the intervention that actually changes the trajectory of the disorder. For medications, the guideline sets strict guardrails. Any pharmacotherapy should be time-limited, targeted at a specific measurable symptom (such as severe insomnia or acute anxiety during a crisis), and adjunctive to psychotherapy — not a standalone treatment. Clinicians should tell patients directly that medications will not address core BPD symptoms and that emotional responses likely cannot be addressed with medications. This is a remarkable statement from the APA. It essentially asks psychiatrists to have an honest conversation with patients about the limits of their prescribing authority — to say, in effect, “I don’t have a pill for this, and I need to stop pretending that I do.”.
The Risks of Treating BPD with Off-Label Medications Long-Term
The dangers of indefinite off-label polypharmacy in BPD are not theoretical. Second-generation antipsychotics like quetiapine and olanzapine carry well-documented risks of weight gain, type 2 diabetes, dyslipidemia, and tardive dyskinesia. These metabolic side effects are cumulative and often irreversible. A patient started on quetiapine at 22 for vaguely defined “mood instability” who remains on it at 40 may have gained 30 or more pounds, developed prediabetes, and never received the psychotherapy that could have addressed the underlying personality pathology. Benzodiazepines present their own hazard.
While sometimes prescribed for the intense anxiety that accompanies BPD, they carry significant risks of dependence, cognitive dulling, and paradoxical disinhibition — the last of which can actually worsen impulsive behavior in BPD patients. The 2024 APA guideline’s recommendation for medication review every six months is aimed squarely at this kind of accumulation: the patient who sees multiple providers, each adding a medication without removing the last one, until the regimen becomes an ungovernable tangle of drugs with overlapping side effects and no clear therapeutic rationale. A critical limitation to acknowledge: some patients with BPD have genuine comorbid conditions — major depression, PTSD, ADHD, bipolar disorder — that do warrant pharmacological treatment. The APA guideline does not say “never prescribe.” It says that medications for comorbidities should be prescribed for the comorbidity, not for BPD itself, and that clinicians must be careful not to attribute all of a patient’s distress to BPD when a treatable comorbid condition may be present. The diagnostic challenge is real, because BPD symptoms overlap substantially with mood and anxiety disorders, and disentangling them requires clinical skill and time.
What BPD Tells Us About the Limits of Biological Psychiatry
BPD is arguably the clearest case study in modern psychiatry of a condition that resists the biomedical model. The field spent decades trying to find a pill for a problem that is fundamentally about how a person learned to experience and respond to emotions, relationships, and identity. This is not to say BPD has no biological dimension — heritable temperamental traits like emotional sensitivity and impulsivity clearly contribute — but the disorder crystallizes through developmental experience, particularly early attachment disruption and trauma.
A drug that dampens amygdala reactivity does not teach a person how to tolerate distress, maintain stable relationships, or develop a coherent sense of self. The BPD experience should give pause to anyone working in brain health more broadly. As the population ages and neurodegenerative conditions rise, the temptation to reach for pharmacological solutions to behavioral and psychological symptoms — whether in dementia, traumatic brain injury, or late-life personality changes — will only intensify. The BPD story is a cautionary reminder: prescribing without evidence, continuing medications by inertia, and neglecting psychosocial interventions carries real costs to patients.
Where BPD Treatment Goes From Here
The 2024 APA guideline may mark a turning point, but changing entrenched prescribing habits will take years. Training programs need to produce more clinicians skilled in DBT and other evidence-based psychotherapies for BPD. Insurance systems need to cover intensive psychotherapy programs without requiring patients to fail multiple medication trials first. And patients themselves need accurate information — that BPD is treatable, that the treatment is psychotherapy, and that the prognosis is actually better than many people assume. Longitudinal studies show that most people with BPD experience significant symptom reduction over 10 years, particularly with appropriate therapeutic support.
Research continues in a few promising directions. Some investigators are exploring ketamine and psilocybin for BPD-related symptoms, though these remain in early-stage trials and face the same endpoint definition problems that plagued earlier studies. Others are working on refining the neurobiological understanding of emotional dysregulation in hopes of identifying more precise drug targets. But the honest assessment is that a BPD-specific medication is not on the near-term horizon. For now, the best evidence points to skilled psychotherapy, honest conversations between clinicians and patients about what medications can and cannot do, and a systematic effort to reduce the polypharmacy that has become the default.
Conclusion
The absence of an FDA-approved medication for borderline personality disorder is not a failure of effort but a reflection of the disorder’s genuine complexity. BPD resists pharmacological treatment because it is not a chemical imbalance — it is a deeply ingrained pattern of emotional, interpersonal, and identity functioning that develops over years and requires psychological, not pharmacological, intervention to change. The 2024 APA Practice Guideline now formally recognizes what the evidence has shown for years: medications play, at best, a narrow adjunctive role in BPD treatment, and the widespread polypharmacy seen in clinical practice is not justified by the evidence.
For patients, families, and clinicians, the path forward is structured psychotherapy — especially dialectical behavior therapy — delivered by trained professionals with adequate time and institutional support. Medications should be reserved for specific, measurable, time-limited targets, reviewed every six months, and tapered when they are not demonstrating clear benefit. The most important step any person with BPD can take is to seek out evidence-based psychotherapy and to understand that while no pill will fix the disorder, real and lasting improvement is achievable through the hard work of therapy.
Frequently Asked Questions
Are there any medications specifically approved by the FDA for borderline personality disorder?
No. As of 2026, there are zero FDA-approved medications for BPD. No regulatory agency anywhere in the world has approved a drug specifically for this condition. All medications currently prescribed for BPD are used off-label.
If medications don’t work for BPD, why do so many psychiatrists still prescribe them?
Several factors drive the high prescribing rate. BPD patients often present in acute crisis, and clinicians feel pressure to intervene quickly. Prescribing is faster and more accessible than arranging specialized psychotherapy. Insurance often covers medications more readily than intensive therapy programs. And once a medication is started, clinical inertia makes it difficult to stop. The 2024 APA guideline is attempting to reverse this pattern.
What is the most effective treatment for borderline personality disorder?
Structured psychotherapy, particularly dialectical behavior therapy, is the most effective treatment with the strongest evidence base. Other evidence-based options include mentalization-based treatment and transference-focused psychotherapy. These therapies directly target the emotional dysregulation, distress intolerance, and interpersonal difficulties that define BPD.
Can someone with BPD also have depression or anxiety that needs medication?
Yes. BPD frequently co-occurs with major depression, PTSD, ADHD, and anxiety disorders. Medications may be appropriate for treating these comorbid conditions. However, the APA guideline emphasizes that clinicians should prescribe for the specific comorbidity, not for BPD itself, and should carefully distinguish BPD symptoms from those of a treatable comorbid condition.
Is borderline personality disorder a lifelong condition?
Longitudinal research shows that most people with BPD experience significant symptom reduction over time, particularly with appropriate therapeutic support. The prognosis is actually better than many clinicians and patients assume. BPD is not a fixed, permanent state — it is a treatable condition with a generally favorable long-term trajectory when evidence-based psychotherapy is available.
What did the Eli Lilly olanzapine trials show about BPD drug treatment?
Eli Lilly sponsored two large-scale randomized controlled trials of olanzapine for BPD, each enrolling more than 300 participants. Both failed to produce the evidence needed for FDA approval. After these high-profile failures, the pharmaceutical industry largely withdrew from large-scale BPD drug development, and no major industry-funded efforts have followed.
